- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:othertreatments:hypoglycemics [10.24.2009] – external edit 127.0.0.1 | home:othertreatments:hypoglycemics [01.03.2012] – external edit 127.0.0.1 | ||
|---|---|---|---|
| Line 2: | Line 2: | ||
| ====== Hypoglycemics | ====== Hypoglycemics | ||
| - | <html>< | + | <relatedarticle> [[home: |
| Line 10: | Line 10: | ||
| Certain adverse effects are associated with use of hyplogycemics. | Certain adverse effects are associated with use of hyplogycemics. | ||
| - | |||
| - | |||
| - | |||
| ===== Types of hypoglycemics ===== | ===== Types of hypoglycemics ===== | ||
| * Avandamet (contains rosiglitazone) | * Avandamet (contains rosiglitazone) | ||
| * exenatide (Byetta) | * exenatide (Byetta) | ||
| + | * nateglinide (Starlix) | ||
| * pioglitazone (Actos) | * pioglitazone (Actos) | ||
| * metformin (Diabex, Glucophage, Glumetza, Ratio-Metformin) | * metformin (Diabex, Glucophage, Glumetza, Ratio-Metformin) | ||
| * rosiglitazone (Avandia) | * rosiglitazone (Avandia) | ||
| - | |||
| Line 29: | Line 26: | ||
| ===== Notes and comments ===== | ===== Notes and comments ===== | ||
| - | EDIT | + | |
| * Legacy content | * Legacy content | ||
| * | * | ||
| ===== References ===== | ===== References ===== | ||
home/othertreatments/hypoglycemics.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.